Literature DB >> 12938147

Impaired protein binding of Chinese medicine DanShen in uremic sera and sera with hyperbilirubinemia: rapid assessment of total and free DanShen concentrations using the fluorescence polarization immunoassay for digoxin.

Amer Wahed1, John Pollard, Alice Wells, Amitava Dasgupta.   

Abstract

DanShen is a Chinese medicine that is used to treat cardiovascular disorders. DanShen is moderately to strongly protein bound, mainly to albumin. Because impaired protein binding of albumin-bound drugs in uremia has been reported, we studied protein binding of DanShen by measuring the digoxin-like immunoreactive component of this Chinese medicine. We observed a significantly higher percentage of free fraction of DanShen in uremic sera in vitro. Impaired protein binding of DanShen was also observed in sera from patients with liver disease, who had elevated concentrations of bilirubin. Treating uremic sera with activated charcoal significantly improved the protein binding of DanShen, indicating that uremic compounds are responsible for the impaired protein binding of DanShen. On the other hand, when various amounts of bilirubin were added to aliquots of the normal pool supplemented with DanShen, we observed only a modest displacement of DanShen from the protein-binding sites by bilirubin, indicating that hypoalbuminemia may play a major role in impaired protein binding of DanShen in sera with elevated bilirubin concentrations. We conclude that protein binding of DanShen is lower in uremic sera and in sera with elevated bilirubin concentrations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938147      PMCID: PMC6807705          DOI: 10.1002/jcla.10090

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  16 in total

1.  Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.

Authors:  R Yuan; J Venitz
Journal:  Int J Clin Pharmacol Ther       Date:  2000-05       Impact factor: 1.366

2.  Protective effect of danshen during myocardial ischemia and reperfusion: an isolated rat heart study.

Authors:  W Zhou; T J Ruigrok
Journal:  Am J Chin Med       Date:  1990       Impact factor: 4.667

Review 3.  An update on digoxin.

Authors:  J A Stone; S J Soldin
Journal:  Clin Chem       Date:  1989-07       Impact factor: 8.327

4.  Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin.

Authors:  A Dasgupta; M J Crossey
Journal:  Am J Med Sci       Date:  1997-02       Impact factor: 2.378

5.  Positive and negative in vitro interference of Chinese medicine dan shen in serum digoxin measurement. Elimination of interference by monitoring free digoxin concentration.

Authors:  A Wahed; A Dasgupta
Journal:  Am J Clin Pathol       Date:  2001-09       Impact factor: 2.493

Review 6.  Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring.

Authors:  E Perucca
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

7.  Evidence-based implementation of free phenytoin therapeutic drug monitoring.

Authors:  M Burt; D C Anderson; J Kloss; F S Apple
Journal:  Clin Chem       Date:  2000-08       Impact factor: 8.327

8.  Isolation and bioactivity of new tanshinones.

Authors:  A R Lee; W L Wu; W L Chang; H C Lin; M L King
Journal:  J Nat Prod       Date:  1987 Mar-Apr       Impact factor: 4.050

9.  Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180.

Authors:  J J Miller; R W Straub; R Valdes
Journal:  Ther Drug Monit       Date:  1996-02       Impact factor: 3.681

10.  Correction of protein binding defect in uremic sera by charcoal treatment.

Authors:  W A Craig; M A Evenson; K P Sarver; J P Wagnild
Journal:  J Lab Clin Med       Date:  1976-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.